New Huntington's drug shows promise in early safety trial
NCT ID NCT06024265
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early phase 1 trial tested an experimental drug called ER2001 in 10 adults with early Huntington's disease. The drug was given by IV at increasing doses over 14 weeks to check safety and how the body processes it. The study also looked for early signs that the drug might affect the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ER2001 (an experimental drug given by intravenous injection)
- What this could lead to
- If successful, this could point toward a treatment that slows or controls Huntington's disease progression.
- What could go wrong
- This is a very early, small (10 people) phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a genetic 'Patch' fix Huntington's disease? lab test aims to find out
- Could a brain disease change behavior years before diagnosis?
- Scientists decode gait signatures to spot brain diseases
- Can a One-Page guide spark better End-of-Life talks for dementia patients?
- Blood test could spot Parkinson's earlier, study hopes
- Can a cooking oil protect the brain in Huntington's?